Non-carbapenem antimicrobial therapy in young infant with urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing Escherichia coli

Jo, Kyo Jin; Yoo, Sukdong; Song, Ji Yeon; Kim, Seong Heon; Park, Su Eun

doi:10.1016/j.pedneo.2021.01.005

Cited by 6 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aminoglycosides, including gentamycin and amikacin, demonstrated complete sensitivity throughout the study period. Notably, gentamycin emerged as the most frequently administered non-carbapenem antimicrobial agent for ESBL cases, followed by amikacin, corroborating earlier studies by Jo et al and Joo and Shin [26,27]. In older infants aged over 2 months, oral cefixime and amoxicillin/clavulanate emerged as the most prescribed antibiotic for non-resistant organisms, in line with our observation.…”

Section: Discussionsupporting

confidence: 91%

Urinary Tract Infections among Febrile Infants in Qatar: Extended-Spectrum-Beta-Lactamase (ESBL)-Producing Versus Non-ESBL Organisms

Qusad,

Elhalabi,

Ali

et al. 2024

Antibiotics

View full text Add to dashboard Cite

Background: The escalating prevalence of ESBL-producing Enterobacteriaceae in Qatar’s pediatric population, especially in community-onset febrile urinary tract infections (FUTIs), necessitates a comprehensive investigation into this concerning trend. Results: Over the course of one year, a total of 459 infants were diagnosed and subsequently treated for UTIs. Cases primarily occurred in infants aged over 60 days, predominantly non-Qatari females born from term pregnancies. Notably, E. coli and K. pneumoniae were the most frequently identified organisms, accounting for 79.7% and 9.8% in the ESBL group and 57.2% and 18.7% in the non-ESBL group, respectively. Interestingly, hydronephrosis emerged as the most prevalent urological anomaly detected in both ESBL (n = 10) and other organism (n = 19) groups. Methods: In this retrospective cohort study conducted in Qatar, we meticulously evaluated the prevalence of pediatric FUTIs. Our study focused on febrile infants aged less than 1 year, excluding those with urine samples not obtained through a catheter. Conclusions: E. coli and K. pneumoniae prevailed as the predominant causative agents in febrile children in Qatar, with hydronephrosis being identified as the most common urological anomaly. Moreover, our findings suggested that gentamicin served as a viable non-carbapenem option for hospitalized ESBL cases, while oral nitrofurantoin showed considerable promise for uncomplicated ESBL UTIs.

show abstract

Section: Discussionsupporting

confidence: 91%

Urinary Tract Infections among Febrile Infants in Qatar: Extended-Spectrum-Beta-Lactamase (ESBL)-Producing Versus Non-ESBL Organisms

Qusad,

Elhalabi,

Ali

et al. 2024

Antibiotics

View full text Add to dashboard Cite

show abstract

“…Also in this study, all isolated ESBL were susceptible to carbapenems. Given the concern about increasing resistance to carbapenems [30], the search for other antibiotics for ESBL UTIs is of great importance. The recommendation to minimize the use of carbapenems was also made by Uyar et al [25].…”

Section: Discussionmentioning

confidence: 99%

Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae in community-acquired urinary tract infections in children and susceptibility to commonly used antibiotic treatments

Rizik

Kassis

Makhoul

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose Enterobacteriaceae producing extended-spectrum beta-lactamase (ESBL) are common pathogens of UTI in children and their prevalence is increasing worldwide. The aim of this study was to determine risk factors for ESBL-positive UTI and susceptibility to antibiotic treatments. Methods A retrospective cohort study conducted at Rambam Health Care Campus, a tertiary hospital in northern Israel. The study included patients younger than < 18 years old and ESBL positive UTI between January 2017 and December 2019. Patient demographics, previous antibiotic treatment, previous UTI episode, genitourinary tract abnormalities, identified organisms in urine cultures, and sensitivity to antibiotics were recorded. Results A total of 570 children who contributed 639 episodes of community-acquired ESBL UTI with 661 Enterobacteriaceae isolates. The median age was 1.3(IQR:0.69–5.9) years. Female comprised 87.9% of the patients. ESBL isolates were identified in 56 (9.8%) patients. Higher rates of resistance to oral antibiotic treatments were found in the ESBL-positive group compared to the ESBL-negative group; amoxicillin-clavulanic acid (65.2% vs 22.7%, p < 0.001, OR = 6.84), trimethoprim-sulfamethoxazole (59.4% vs 17.6%, p < 0.001, OR = 6.84), ciprofloxacin (34.8% vs 4.5%, p < 0.001, OR = 11.43), and to piperacillin-tazobactam (27.5% vs 6.4%, p < 0.001, OR = 5.54). Neither group was resistant to amikacin or carbapenem. Risk factors for ESBL-positive UTI were antibiotic treatment within the last three months (p = 0.002, OR = 3.68, CI:1.63–8.31) and known ESBL carriage (p < 0.001, OR = 13.18, CI:4.25–40.94). Conclusions Known ESBL carriage and recent antibiotic treatment were risk factors for ESBL UTI. High rate of resistance to oral empiric and prophylactic antibiotic treatments was detected. Amikacin as initial treatment in anticipation of culture susceptibility is reasonable.

show abstract

“…The ESBLs-producing bacteria confer resistance to β-lactams antibiotics, especially the third and fourth-generation extended-spectrum β-lactam antibiotics. Moreover, ESBLs-producing bacteria also typically exhibit resistance to other classes of antibiotics, and express the multidrug resistance ( MDR ) phenotype ( Jo et al, 2021 ). MDR isolates have escalated and become a significant cause of morbidity and mortality worldwide ( Lay et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Antibacterial and antibiofilm activity of Lagotis brachystachya extract against extended-spectrum β-lactamases-producing Escherichia coli from broiler chickens

et al. 2022

View full text Add to dashboard Cite

Lagotis brachystachya Maxim ( L. brachystachya ) is an herb widely used in traditional Tibetan medicine. In the present study, the antibacterial activity of L. brachystachya extract to extended-spectrum-lactamases ( ESBLs )-producing E. coli was determined by Kirby-Bauer disc diffusion, minimum inhibitory concentrations ( MICs ) and minimum bactericidal concentrations ( MBCs ) methods as well as time-kill curve assay. Meanwhile, the biofilm inhibition and eradication effects of L. brachystachya extract on the ESBLs-producing E. coli were evaluated by crystal violet staining, and further confirmed by confocal laser scanning microscope ( CLSM ) and scanning electron microscopy ( SEM ). The results indicated that L. brachystachya extract exhibited moderate antibacterial activity, with diameter of inhibition zones varying from 15.4 to 20.3 mm, and the MIC and MBC values were 6.25 to 25 mg/mL and 12.5 to 100 mg/mL, respectively. Time-kill curve showed that 4 × MIC level of L. brachystachya extract concentration of was able to kill 99.9% of ESBLs-producing E. coli after 16 h treatment. The biofilm inhibition rate and eradication rate for the ESBLs-producing E. coli were 35.66 to 79.91% and 22.18 to 56.21% at MIC level of extract concentration, respectively. CLSM images showed that the biofilm became thinner as the ESBLs-producing E. coli isolate exposed to L. brachystachya extract with a concentration-dependent manner from 1/4 × MIC to MIC compared with the control isolate. SEM images indicated that L. brachystachya extract at 1/2 × MIC and MIC levels could evidently inhibit the biofilm formation or eradicate the mature biofilms. The effect of L. brachystachya highlights its potential of antibacterial and antibiofilm activities against the ESBLs-producing E. coli .

show abstract

Non-carbapenem antimicrobial therapy in young infant with urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing Escherichia coli

Cited by 6 publications

References 38 publications

Urinary Tract Infections among Febrile Infants in Qatar: Extended-Spectrum-Beta-Lactamase (ESBL)-Producing Versus Non-ESBL Organisms

Urinary Tract Infections among Febrile Infants in Qatar: Extended-Spectrum-Beta-Lactamase (ESBL)-Producing Versus Non-ESBL Organisms

Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae in community-acquired urinary tract infections in children and susceptibility to commonly used antibiotic treatments

Antibacterial and antibiofilm activity of Lagotis brachystachya extract against extended-spectrum β-lactamases-producing Escherichia coli from broiler chickens

Contact Info

Product

Resources

About